A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Inclusion Criteria:

- Previously untreated CD20-positive DLBCL

- At least 1 bi-dimensionally measurable lesion (greater than [>]1.5 centimeters [cm] in
its largest dimension on the computed tomography [CT] scan)

- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

- Adequate hematological function

- Low-intermediate, high-intermediate or high-risk International Prognostic Index (IPI)
score (low-risk IPI score: IPI 1 irrespective of bulky disease or IPI 0 with bulky
disease, defined as one lesion greater than equal to (>/=) 7.5 cm)

- Left ventricular ejection fraction (LVEF) >/=50 percent (%) on cardiac multiple-gated
acquisition (MUGA) scan or cardiac echocardiogram

Exclusion Criteria:

- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
antibodies or known sensitivity or allergy to murine products or to any component of
CHOP or obinutuzumab

- Contraindication to any of the individual components of CHOP, including prior receipt
of anthracyclines

- Participants with transformed lymphoma and participants with follicular lymphoma IIIB

- Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation

- Prior treatment with cytotoxic drugs or rituximab for another condition (for example,
rheumatoid arthritis) or prior use of an anti-CD20 antibody

- Prior use of any monoclonal antibody within 3 months of the start of Cycle 1

- Corticosteroid use of >30 milligrams per day (mg/day) of prednisone or equivalent, for
purposes other than lymphoma symptom control

- Primary central nervous system (CNS) lymphoma and secondary CNS involvement by
lymphoma, mantle-cell lymphoma (MCL), or histologic evidence of transformation to a
Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, plasmablastic
lymphoma, and primary cutaneous DLBCL